
Shin Hon Chen
Examiner (ID: 706, Phone: (571)272-3789 , Office: P/2431 )
| Most Active Art Unit | 2431 |
| Art Unit(s) | 2131, 2431 |
| Total Applications | 1314 |
| Issued Applications | 1098 |
| Pending Applications | 88 |
| Abandoned Applications | 152 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17124315
[patent_doc_number] => 20210299083
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => Novel Uses of Halogenated Xanthenes in Oncology and Virology
[patent_app_type] => utility
[patent_app_number] => 17/212723
[patent_app_country] => US
[patent_app_date] => 2021-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14600
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 121
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17212723
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/212723 | Uses of halogenated xanthenes in oncology and virology | Mar 24, 2021 | Issued |
Array
(
[id] => 19233668
[patent_doc_number] => 20240190860
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/551942
[patent_app_country] => US
[patent_app_date] => 2021-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23437
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 333
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18551942
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/551942 | 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | Mar 23, 2021 | Pending |
Array
(
[id] => 18683850
[patent_doc_number] => 11779560
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-10
[patent_title] => Methods of using nitric oxide donor compounds for treatment of COVID-19 and other infectious diseases
[patent_app_type] => utility
[patent_app_number] => 17/211778
[patent_app_country] => US
[patent_app_date] => 2021-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 14
[patent_no_of_words] => 11393
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17211778
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/211778 | Methods of using nitric oxide donor compounds for treatment of COVID-19 and other infectious diseases | Mar 23, 2021 | Issued |
Array
(
[id] => 16930841
[patent_doc_number] => 20210196730
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-01
[patent_title] => COMPOUND AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/203758
[patent_app_country] => US
[patent_app_date] => 2021-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17159
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17203758
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/203758 | COMPOUND AND USE THEREOF | Mar 16, 2021 | Abandoned |
Array
(
[id] => 16932372
[patent_doc_number] => 20210198261
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-01
[patent_title] => AURORA KINASE INHIBITORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/200854
[patent_app_country] => US
[patent_app_date] => 2021-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8223
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 120
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17200854
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/200854 | Aurora kinase inhibitors and uses thereof | Mar 13, 2021 | Issued |
Array
(
[id] => 17110168
[patent_doc_number] => 20210290765
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-23
[patent_title] => SURFACTANTS FOR HEALTHCARE PRODUCTS
[patent_app_type] => utility
[patent_app_number] => 17/196998
[patent_app_country] => US
[patent_app_date] => 2021-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19059
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 168
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17196998
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/196998 | SURFACTANTS FOR HEALTHCARE PRODUCTS | Mar 8, 2021 | Pending |
Array
(
[id] => 18861863
[patent_doc_number] => 20230416298
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-28
[patent_title] => PRODRUGS OF NEUROACTIVE STEROIDS
[patent_app_type] => utility
[patent_app_number] => 17/801894
[patent_app_country] => US
[patent_app_date] => 2021-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26508
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -51
[patent_words_short_claim] => 339
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17801894
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/801894 | PRODRUGS OF NEUROACTIVE STEROIDS | Feb 28, 2021 | Pending |
Array
(
[id] => 18360747
[patent_doc_number] => 20230142338
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING
[patent_app_type] => utility
[patent_app_number] => 17/802866
[patent_app_country] => US
[patent_app_date] => 2021-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59762
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17802866
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/802866 | THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING | Feb 27, 2021 | Pending |
Array
(
[id] => 17183718
[patent_doc_number] => 20210330603
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => METHODS OF USING CANNABINOIDS FOR INHIBITING INDUCTION OF VIRULENCE IN ENTERIC PATHOGENS
[patent_app_type] => utility
[patent_app_number] => 17/184350
[patent_app_country] => US
[patent_app_date] => 2021-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12179
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17184350
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/184350 | METHODS OF USING CANNABINOIDS FOR INHIBITING INDUCTION OF VIRULENCE IN ENTERIC PATHOGENS | Feb 23, 2021 | Abandoned |
Array
(
[id] => 17383763
[patent_doc_number] => 20220031615
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => VESICLES
[patent_app_type] => utility
[patent_app_number] => 17/181796
[patent_app_country] => US
[patent_app_date] => 2021-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15610
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17181796
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/181796 | VESICLES | Feb 21, 2021 | Abandoned |
Array
(
[id] => 19209499
[patent_doc_number] => 11998534
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-04
[patent_title] => GPX4 inhibitor in combination with anticancer agent for treating proliferative disease
[patent_app_type] => utility
[patent_app_number] => 17/173416
[patent_app_country] => US
[patent_app_date] => 2021-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 6
[patent_no_of_words] => 27052
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17173416
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/173416 | GPX4 inhibitor in combination with anticancer agent for treating proliferative disease | Feb 10, 2021 | Issued |
Array
(
[id] => 17034988
[patent_doc_number] => 20210251946
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => CANNABINOID-CONTAINING EXTRACTS, FORMULATIONS, AND USES THEREOF FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS
[patent_app_type] => utility
[patent_app_number] => 17/168524
[patent_app_country] => US
[patent_app_date] => 2021-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8755
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17168524
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/168524 | CANNABINOID-CONTAINING EXTRACTS, FORMULATIONS, AND USES THEREOF FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Feb 4, 2021 | Abandoned |
Array
(
[id] => 18389803
[patent_doc_number] => 20230158021
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => SARS-CoV-2 Antiviral Pharmaceutical Composition and Application Thereof
[patent_app_type] => utility
[patent_app_number] => 17/922581
[patent_app_country] => US
[patent_app_date] => 2021-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2505
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17922581
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/922581 | SARS-CoV-2 Antiviral Pharmaceutical Composition and Application Thereof | Feb 3, 2021 | Abandoned |
Array
(
[id] => 18725683
[patent_doc_number] => 20230339854
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => Negative Allosteric Modulation of GluN3-Containing N-Methyl-D-Aspartate Receptors
[patent_app_type] => utility
[patent_app_number] => 17/796387
[patent_app_country] => US
[patent_app_date] => 2021-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36820
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17796387
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/796387 | Negative Allosteric Modulation of GluN3-Containing N-Methyl-D-Aspartate Receptors | Jan 31, 2021 | Abandoned |
Array
(
[id] => 16977530
[patent_doc_number] => 20210221767
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-22
[patent_title] => Crystalline Forms of Zuclomiphene Citrate
[patent_app_type] => utility
[patent_app_number] => 17/154261
[patent_app_country] => US
[patent_app_date] => 2021-01-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6605
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17154261
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/154261 | Crystalline forms of zuclomiphene citrate | Jan 20, 2021 | Issued |
Array
(
[id] => 16946621
[patent_doc_number] => 20210205312
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-08
[patent_title] => TREATMENT OF MEMBRANOUS NEPHROPATHY, IGG4-RELATED DISEASE, AND ANTIPHOSPHOLIPID SYNDROME USING BTK INHIBITOR 2-[(3R)-3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-d]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE
[patent_app_type] => utility
[patent_app_number] => 17/141930
[patent_app_country] => US
[patent_app_date] => 2021-01-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7337
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17141930
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/141930 | TREATMENT OF MEMBRANOUS NEPHROPATHY, IGG4-RELATED DISEASE, AND ANTIPHOSPHOLIPID SYNDROME USING BTK INHIBITOR 2-[(3R)-3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-d]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE | Jan 4, 2021 | Pending |
Array
(
[id] => 18193096
[patent_doc_number] => 20230046615
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => BIOMASS-BASED PESTICIDES AND METHODS OF MAKING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/783316
[patent_app_country] => US
[patent_app_date] => 2020-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11226
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17783316
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/783316 | BIOMASS-BASED PESTICIDES AND METHODS OF MAKING THE SAME | Dec 20, 2020 | Pending |
Array
(
[id] => 18176708
[patent_doc_number] => 20230037437
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => FORMULATIONS FOR USE IN THE TREATMENT OF DIFFERENT TYPES OF ADDICTIONS AND DEPENDENCE ON ADDICTIVE SUBSTANCES
[patent_app_type] => utility
[patent_app_number] => 17/787510
[patent_app_country] => US
[patent_app_date] => 2020-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11327
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -135
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17787510
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/787510 | FORMULATIONS FOR USE IN THE TREATMENT OF DIFFERENT TYPES OF ADDICTIONS AND DEPENDENCE ON ADDICTIVE SUBSTANCES | Dec 13, 2020 | Abandoned |
Array
(
[id] => 19140433
[patent_doc_number] => 20240139216
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-02
[patent_title] => STABLE ORAL CANNABIDIOL COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/265509
[patent_app_country] => US
[patent_app_date] => 2020-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8453
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18265509
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/265509 | STABLE ORAL CANNABIDIOL COMPOSITIONS | Dec 6, 2020 | Pending |
Array
(
[id] => 18139833
[patent_doc_number] => 20230013669
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => Antibacterial Treatment Using a Cannabinoid and an Active Agent
[patent_app_type] => utility
[patent_app_number] => 17/778910
[patent_app_country] => US
[patent_app_date] => 2020-11-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23514
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778910
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/778910 | Antibacterial Treatment Using a Cannabinoid and an Active Agent | Nov 26, 2020 | Abandoned |